MissionIR Articles

VistaGen Therapeutics, Inc., a biotechnology company applying stem cell technology for drug rescue and cell therapy, just announced the publication of its original research demonstrating the use of pluripotent stem cells to generate insulin in…

When VistaGen Therapeutics announced the appointment of Shawn K. Singh as its CEO, Mr. Singh’s reputation and familiarity with the company had already been established. As Managing Principal of Cato BioVentures, VistaGen’s biggest institutional stockholder,…

The good news is that new pharmaceutical discoveries are being made nearly every day for the treatment of life threatening diseases. The bad news is that, after hundreds of millions of dollars spent to identify…

VistaGen Therapeutics, Inc., a biotechnology company primarily focused on applying stem cell technology for drug rescue and cell therapy, today provides a comprehensive update on the Company’s strategic plan to develop and commercialize its technology…

Few advances in the history of human health have raised as much hope as the development and application of pluripotent stem cell technology. It’s an enthusiasm based on the fact that pluripotent stem cells, unlike…

Like a number of other growing companies, VistaGen Therapeutics, a biotech company applying stem cell technology for drug rescue and cell therapy, plans to use the OTC Bulletin Board as an important starting point for…

VistaGen Therapeutics, Inc., a biotechnology company focused on stem cell-based drug rescue and drug development, recently completed a $3.87 million financing (including cancellation of $1.0 million of debt) to accredited investors, including a $1.5 million…

Excaliber Enterprises, Ltd. (OTC Bulletin Board: EXCA) announced today that its wholly-owned subsidiary has merged (the Merger) with VistaGen Therapeutics, Inc. (VistaGen), a private biotechnology company focused on stem cell-based drug rescue and drug development.…

VistaGen Therapeutics, Inc. and NuPotential, Inc. today announced that the National Heart, Lung and Blood Institute of the U.S. National Institutes of Health (NIH) has awarded to the companies a grant of approximately $500,000 to…

VistaGen Therapeutics, Inc., a stem cell technology company focused on drug discovery and development, today announced the successful completion of its initial Phase 1 safety study of AV-101, the Company’s novel orally available prodrug candidate…

VistaGen Therapeutics has named Shawn K. Singh as Chief Executive Officer. Mr. Singh was Managing Principal of Cato BioVentures, one of VistaGen’s largest institutional investors, and the Company’s President (part-time). Mr. Singh also served as…

VistaGen and Capsant have signed a strategic commercialization agreement under which the companies will combine their leading-edge stem cell biology and 3D cell culture platforms, respectively, to advance their mutual business interests worldwide. The new…

VistaGen Therapeutics and the Wisconsin Alumni Research Foundation (WARF) have signed a license for human embryonic stem cell patents for the development and commercialization of stem cell-based research tools. VistaGen is one of the world’s…

VistaGen Therapeutics announced today that the California Institute for Regenerative Medicine (CIRM), the State’s stem cell agency, has awarded a major grant to the Company to expand ongoing development and commercialization of its leading-edge stem…

Researchers from VistaGen Therapeutics, together with Dr. Gordon Keller and his team of scientists from Toronto’s McEwen Centre for Regenerative Medicine and the Mount Sinai School of Medicine, have successfully identified key biochemical pathways involved…

VistaGen Therapeutics, Inc., a biotechnology company using leading-edge embryonic stem cell (ES Cell) technologies for predictive toxicology and drug discovery, has announced new broad composition of matter patent protection for its ES Cell-derived pluripotent precursor…

VistaGen Therapeutics, Inc., a biotechnology company using leading-edge embryonic stem cell (ES Cell) technologies for predictive toxicology and drug discovery, today announced that Sanwa Kagaku Kenkyusho Co. Ltd. (Sanwa), an international pharmaceutical company headquartered in…

Joined by scientists from VistaGen Therapeutics here, a team of leading Canadian, American and British medical researchers have used embryonic stem (ES) cells differentiation cultures to successfully identify, grow and study the earliest cell destined…

VistaGen Therapeutics, Inc., a biotechnology company using embryonic stem (ES) cell technologies to discover and develop new drugs for diabetes and neurological disorders, today announced an expansive ES cell research alliance with Toronto’s University Health…